GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, and Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process..

GenScript Biotech Corporation（GenScript），世界领先的生命科学研究工具和服务提供商之一，以及开发行业领先的自动化制造系统以生产个性化药物的机器人公司Multiply Labs，今天宣布围绕细胞治疗制造的细胞分离阶段的自动化建立战略伙伴关系，降低了这一费力过程的复杂性。。

Cell isolation using immunomagnetic beads is a critical industry-standard process in cell therapy manufacturing. However, the current method of performing this task manually is complex and time-consuming. In addition to the sensitivity of cells, intricate process and precision required, the approach requires manually handling, connecting and double-checking complex closed-system consumable kits..

使用免疫磁珠进行细胞分离是细胞治疗制造中的关键行业标准流程。然而，目前手动执行此任务的方法复杂且耗时。除了电池的灵敏度、复杂的过程和所需的精度外，该方法还需要手动处理、连接和双重检查复杂的封闭系统耗材套件。。

By utilizing Multiply Labs' cell therapy robotic cluster and GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour, this collaboration will introduce the first fully automated solution for bead-based cell isolation. Importantly, this automation technology will not require cell therapy manufacturers to make substantial modifications to their original manufacturing processes..

通过利用Multiply Labs的细胞治疗机器人集群和GenScript的GMP级CytoSinct 1000细胞分离解决方案，能够在一个小时内分离多达120X10 ^ 9个总细胞，该合作将引入第一个基于珠子的全自动细胞分离解决方案。重要的是，这种自动化技术不需要细胞疗法制造商对其原始制造工艺进行实质性修改。。

This advancement promises to mitigate the risk of human error while simultaneously boosting cell therapy output. Once this part of the process can be run without human intervention, manufacturing operators and process scientists will be free to oversee the production of more therapies at once, without being tied down in the delicate, tedious, and mission-critical manual tasks involved in the traditional manufacturing process.

这一进步有望减轻人为错误的风险，同时提高细胞疗法的产量。一旦这部分过程可以在没有人为干预的情况下运行，制造操作员和过程科学家将可以自由地同时监督更多疗法的生产，而不会被传统制造过程中涉及的微妙，繁琐和关键任务的手动任务所束缚。

Automation in this deeply time-consuming area of the process will therefore drive significant benefits around efficiency, and ultimately support the scalability of cell therapies.'Our collaboration with Multiply Labs marks a significant advancement in personalized medicine and the potential impact of cell therapies,' said Ray Chen, PhD, President of Life Science Group at GenScript.

因此，该过程中这一非常耗时的领域的自动化将为效率带来重大益处，并最终支持细胞疗法的可扩展性。”GenScript生命科学组总裁Ray Chen博士说，我们与Multiply Labs的合作标志着个性化医学和细胞疗法的潜在影响取得了重大进展。

'By automating our industry-leading solution, we can dramatically increase productivity and scale operations to unprecedented levels.''We're thrilled to partner with GenScript to enhance a critical aspect of the cell therapy process through automation,' said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs.

“通过自动化我们业界领先的解决方案，我们可以大幅提高生产力，并将运营规模扩大到前所未有的水平。”Multiply Labs联合创始人兼首席执行官弗雷德·帕里蒂（FredParietti）博士说，我们很高兴与GenScript合作，通过自动化增强细胞治疗过程的关键方面。

'This collaboration advances our goal of a fully automated, end-to-end therapy manufacturing process, reducing costs and expanding patient access to life-changing treatments.'About Multiply LabsMultiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry.

“这种合作推进了我们的目标，即实现全自动化、端到端的治疗制造流程，降低成本，扩大患者获得改变生活的治疗的机会。”关于Multiply Labs Multiply Labs是一家机器人公司，为制药行业提供自主制造技术。

The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs' expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, e.

该公司开发了先进的云控制机器人系统，可以大规模生产个性化药物。其客户包括先进制药制造领域的一些最大的全球组织。Multiply实验室的专业知识是机器人技术和生物制药的交叉点，其团队包括机械工程师e。